Lipella Pharmaceuticals Inc.
â—‹
Search Organization
announced the issuance of U.S. Patent No. 12,138,345 for its liposomal drug delivery platform, covering the use of metastable liposomes to deliver therapeutic agents. This patent extends market exclusivity for Lipella’s lead assets, LP-10 and LP-310, currently in Phase 2 trials for hemorrhagic cystitis and oral lichen planus, respectively.